Literature DB >> 2874958

Terfenadine in chronic urticaria: a comparison with clemastine and placebo.

T Fredriksson, K Hersle, N Hjorth, H Mobacken, T Persson, L Salde, O Salo, H Schmidt, K Thomsen.   

Abstract

Terfenadine, a new specific and peripherally acting antihistamine, was compared with clemastine and placebo in a prospective, randomized, double-blind, double-dummy, crossover study of the treatment of chronic urticaria. Sixty patients with chronic urticaria participated in this multicenter trial. The treatment time was two weeks per drug treatment, totalling six weeks. Terfenadine proved more effective than clemastine and was associated with significantly less sedation. Few adverse reactions were noted.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2874958

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  3 in total

Review 1.  Terfenadine. The first nonsedating antihistamine.

Authors:  H C Masheter
Journal:  Clin Rev Allergy       Date:  1993

Review 2.  Terfenadine. An updated review of its pharmacological properties and therapeutic efficacy.

Authors:  D McTavish; K L Goa; M Ferrill
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

Review 3.  The KAAACI/KDA Evidence-Based Practice Guidelines for Chronic Spontaneous Urticaria in Korean Adults and Children: Part 1. Definition, Methodology and First-line Management.

Authors:  Woo Jung Song; Mira Choi; Dong Hun Lee; Jae Woo Kwon; Gun Woo Kim; Myung Hwa Kim; Mi Ae Kim; Min Hye Kim; Byung Keun Kim; Sujeong Kim; Joung Soo Kim; Jung Eun Kim; Ju Young Kim; Joo Hee Kim; Hyun Jung Kim; Hye One Kim; Hyo Bin Kim; Joo Young Roh; Kyung Hee Park; Kui Young Park; Han Ki Park; Hyunsun Park; Jung Min Bae; Ji Yeon Byun; Dae Jin Song; Young Min Ahn; Seung Eun Lee; Young Bok Lee; Joong Sun Lee; Ji Hyun Lee; Kyung Hwan Lim; Young Min Ye; Yoon Seok Chang; You Hoon Jeon; Jiehyun Jeon; Mihn Sook Jue; Sun Hee Choi; Jeong Hee Choi; Gyu Young Hur; Young Min Park; Dae Hyun Lim; Sang Woong Youn
Journal:  Allergy Asthma Immunol Res       Date:  2020-07       Impact factor: 5.764

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.